Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Nielsen, R, Jorsal, A, Tougaard, RS, Rasmussen, JJ, Schou, M, Videbaek, L, Gustafsson, I, Faber, J, Flyvbjerg, A, Wiggers, H, Tarnow, L & Kistorp, C 2020, 'The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes', Diabetes, Obesity and Metabolism, bind 22, nr. 11, olume22, Issue11 November 2020 Pages 2141-2150, s. 2141-2150. https://doi.org/10.1111/dom.14135

APA

Nielsen, R., Jorsal, A., Tougaard, R. S., Rasmussen, J. J., Schou, M., Videbaek, L., Gustafsson, I., Faber, J., Flyvbjerg, A., Wiggers, H., Tarnow, L., & Kistorp, C. (2020). The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes. Diabetes, Obesity and Metabolism, 22(11), 2141-2150. [olume22, Issue11 November 2020 Pages 2141-2150]. https://doi.org/10.1111/dom.14135

CBE

MLA

Vancouver

Author

Nielsen, Roni ; Jorsal, Anders ; Tougaard, Rasmus Stilling ; Rasmussen, Jon Jarløv ; Schou, Morten ; Videbaek, Lars ; Gustafsson, Ida ; Faber, Jens ; Flyvbjerg, Allan ; Wiggers, Henrik ; Tarnow, Lise ; Kistorp, Caroline. / The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes. I: Diabetes, Obesity and Metabolism. 2020 ; Bind 22, Nr. 11. s. 2141-2150.

Bibtex

@article{16de30b047a642d58529e2eca6f6f9c1,
title = "The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes",
abstract = "Aim: To assess the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). Materials and methods: In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D. Plasma levels of N-terminal brain-natriuretic-peptide (NT-proBNP) (a predefined secondary endpoint), midregional pro-atrial-natriuretic-peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM) and copeptin were measured at baseline and after 24 weeks in this substudy. The potential effect modification of T2D was assessed. Results: In the eligible subgroup of 231 patients with available biomarkers (115 randomized to liraglutide and 116 to placebo), MR-proANP decreased by 12% (P =.002) and NT-proBNP by 9% (P =.009) during liraglutide treatment compared with placebo at week 24. Interaction with T2D for the treatment effect of change in MR-proANP and NT-proBNP levels was P =.003 and P =.03, respectively. Consequently, in patients with T2D, liraglutide decreased MR-proANP by 27% (P <.001) and NT-proBNP by 25% (P =.02) compared with placebo, whereas no change was observed in patients without T2D. There was no effect of liraglutide on MR-proADM (P =.10) or copeptin (P =.52). Conclusion: Liraglutide decreased the A- and B-type natriuretic peptides significantly in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant T2D, suggesting a beneficial mechanism of liraglutide in T2D patients with HFrEF.",
keywords = "GLP-1 analogue, heart failure, type 2 diabetes",
author = "Roni Nielsen and Anders Jorsal and Tougaard, {Rasmus Stilling} and Rasmussen, {Jon Jarl{\o}v} and Morten Schou and Lars Videbaek and Ida Gustafsson and Jens Faber and Allan Flyvbjerg and Henrik Wiggers and Lise Tarnow and Caroline Kistorp",
note = "{\textcopyright} 2020 John Wiley & Sons Ltd.",
year = "2020",
month = nov,
doi = "10.1111/dom.14135",
language = "English",
volume = "22",
pages = "2141--2150",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "11",

}

RIS

TY - JOUR

T1 - The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes

AU - Nielsen, Roni

AU - Jorsal, Anders

AU - Tougaard, Rasmus Stilling

AU - Rasmussen, Jon Jarløv

AU - Schou, Morten

AU - Videbaek, Lars

AU - Gustafsson, Ida

AU - Faber, Jens

AU - Flyvbjerg, Allan

AU - Wiggers, Henrik

AU - Tarnow, Lise

AU - Kistorp, Caroline

N1 - © 2020 John Wiley & Sons Ltd.

PY - 2020/11

Y1 - 2020/11

N2 - Aim: To assess the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). Materials and methods: In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D. Plasma levels of N-terminal brain-natriuretic-peptide (NT-proBNP) (a predefined secondary endpoint), midregional pro-atrial-natriuretic-peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM) and copeptin were measured at baseline and after 24 weeks in this substudy. The potential effect modification of T2D was assessed. Results: In the eligible subgroup of 231 patients with available biomarkers (115 randomized to liraglutide and 116 to placebo), MR-proANP decreased by 12% (P =.002) and NT-proBNP by 9% (P =.009) during liraglutide treatment compared with placebo at week 24. Interaction with T2D for the treatment effect of change in MR-proANP and NT-proBNP levels was P =.003 and P =.03, respectively. Consequently, in patients with T2D, liraglutide decreased MR-proANP by 27% (P <.001) and NT-proBNP by 25% (P =.02) compared with placebo, whereas no change was observed in patients without T2D. There was no effect of liraglutide on MR-proADM (P =.10) or copeptin (P =.52). Conclusion: Liraglutide decreased the A- and B-type natriuretic peptides significantly in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant T2D, suggesting a beneficial mechanism of liraglutide in T2D patients with HFrEF.

AB - Aim: To assess the effect of liraglutide, a glucagon-like peptide-1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). Materials and methods: In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D. Plasma levels of N-terminal brain-natriuretic-peptide (NT-proBNP) (a predefined secondary endpoint), midregional pro-atrial-natriuretic-peptide (MR-proANP), midregional pro-adrenomedullin (MR-proADM) and copeptin were measured at baseline and after 24 weeks in this substudy. The potential effect modification of T2D was assessed. Results: In the eligible subgroup of 231 patients with available biomarkers (115 randomized to liraglutide and 116 to placebo), MR-proANP decreased by 12% (P =.002) and NT-proBNP by 9% (P =.009) during liraglutide treatment compared with placebo at week 24. Interaction with T2D for the treatment effect of change in MR-proANP and NT-proBNP levels was P =.003 and P =.03, respectively. Consequently, in patients with T2D, liraglutide decreased MR-proANP by 27% (P <.001) and NT-proBNP by 25% (P =.02) compared with placebo, whereas no change was observed in patients without T2D. There was no effect of liraglutide on MR-proADM (P =.10) or copeptin (P =.52). Conclusion: Liraglutide decreased the A- and B-type natriuretic peptides significantly in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant T2D, suggesting a beneficial mechanism of liraglutide in T2D patients with HFrEF.

KW - GLP-1 analogue

KW - heart failure

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85089312606&partnerID=8YFLogxK

U2 - 10.1111/dom.14135

DO - 10.1111/dom.14135

M3 - Journal article

C2 - 32627271

VL - 22

SP - 2141

EP - 2150

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 11

M1 - olume22, Issue11 November 2020 Pages 2141-2150

ER -

ID: 60282793